Superworth

Corcept Therapeutics CORT

Drug Manufacturers - General, Healthcare
$80.46
−0.81%
Market cap
$8.7B
PE
192×
10y median 28.3×
Forward PE
n/m
not a meaningful number
Price to sales
10.5×
EV/EBIT
n/m
a sliver of operating profit
Revenue, 12 months
$830.8M
+16% on a year ago
Net margin
6.6%
Free cash flow yield
1.2%

Corcept Therapeutics trades at 192× trailing earnings, pricier than 93% of the last ten years. Revenue was $830.8M over the last twelve months, up 16% on a year earlier with a 7% net margin.

Charts

Financials

Income statement for CORT, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$123.6M+22%$135.4M+31%$146.8M+39%$163.8M+39%$182.5M+48%$181.9M+34%$157.2M+7%$194.4M+19%$207.6M+14%$202.1M+11%$164.9M+5%$256.1M+32%
Cost of revenue$1.6M+23%$1.9M+27%$2.5M+83%$2.5M+60%$2.9M+74%$3M+58%$2.4M−5%$3.4M+36%$4.6M+60%$2.5M−14%$2.9M+20%$4.1M+18%
Gross profit$122M+22%$133.5M+32%$144.3M+38%$161.3M+39%$179.7M+47%$178.9M+34%$154.8M+7%$191M+18%$203M+13%$199.6M+12%$162M+5%$252.1M+32%
R&D$45.5M+37%$54.7M+49%$58.5M+43%$58.7M+36%$59.3M+30%$70.3M+29%$60.7M+4%$60.5M+3%$68.8M+16%$64.9M−8%$66.3M+9%$53.9M−11%
SG&A$45.3M+29%$47.2M+11%$56.3M+16%$66.9M+55%$73.7M+63%$83.4M+77%$90.7M+61%$103.9M+55%$124M+68%$130.2M+56%$145.4M+60%$156.9M+51%
$31.2M−2%$31.7M+41%$29.5M+99%$35.6M+20%$46.6M+50%$25.3M−20%$3.4M−88%$26.7M−25%$10.2M−78%$4.5M−82%−$49.6M$41.3M+55%
Interest expensen/an/an/an/an/an/an/an/an/an/an/an/a
Pre-tax income$36.4M+10%$36.8M+52%$35M+90%$41.6M+26%$52.9M+46%$32M−13%$9.6M−73%$31.7M−24%$15.2M−71%$9.9M−69%−$44.7M$45.9M+45%
$5M$5.5M−29%$7.2M+183%$6.1M+13%$5.7M+14%$1.2M−78%−$10.9M−$3.5M−$4.4M−$14.4M−$13M+19%$2.9M
Net income$31.4M−9%$31.4M+89%$27.8M+75%$35.5M+29%$47.2M+51%$30.7M−2%$20.5M−26%$35.1M−1%$19.7M−58%$24.3M−21%−$31.8M$43M+22%
$0.28−7%$0.28+100%$0.25+79%$0.32+28%$0.41+46%$0.26−7%$0.17−32%$0.29−9%$0.16−61%$0.20−23%−$0.30$0.36+24%
111.1M−5%110.8M−5%109.9M−5%111.2M+2%113.7M+2%119.2M+8%119.8M+9%120.5M+8%119.4M+5%120M+1%104.4M−13%118.4M−2%

Gross profit: 57 periods, Q2 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 7 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY10 and Q4 FY11: not printed by the filing, worked out from its own lines. 3 periods, Q4 FY12 to Q4 FY14: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY15 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CORTCorcept Therapeutics$8.7B192×28.3×10.5×+16%6.6%
PTGXProtagonist Therapeutics$9B135×60.1×32.0×+35%29.4%
TGTXTG Therapeutics$9.2B21.9×19.6×11.5×+76%55.2%
ALKSAlkermes plc.$7.5B118×16.0×4.5×+11%4.0%
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
BMRNBiomarin Pharmaceutical$11.1B155×72.5×3.3×+11%2.1%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
JAZZJazz Pharmaceuticals$13.9B14.7×20.1×3.0×+13%20.4%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
Peer median$7.3B67.7×44.5×6.5×+26%15.0%

More on Corcept Therapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .